Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 3, 2015, Pages 256-264

  Murphy, Joseph ^a   Wang, Shean Sheng ^a   Stieltjes, Hans ^b   Wajs, Ewa ^b   Devineni, Damayanthi ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Canagliflozin; Fixed dose combination; Food effect; Metformin; Pharmacokinetics; Sodium glucose co transporter 2 inhibitor

Indexed keywords

CANAGLIFLOZIN PLUS METFORMIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DRUG COMBINATION; GLUCOSIDE; METFORMIN; TABLET; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; NORMAL HUMAN; NUTRITIONAL ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; DRUG COMBINATION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; TABLET; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG COMBINATIONS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; GLUCOSIDES; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; METFORMIN; MIDDLE AGED; POSTPRANDIAL PERIOD; TABLETS; THERAPEUTIC EQUIVALENCY; THIOPHENES; YOUNG ADULT;

EID: 84938525379     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202233     Document Type: Article

References (33)

1. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154-2161.
2. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669-672.
3. Canagliflozin (Invokana™) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204042s000lbl.pdf. Accessed on March 5, 2014; 2013.
4. Canagliflozin (Invokana™) Summary of Product Characteristics. Beerse, Belgium: Janssen-Cilag International NV. 2013. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/002649/WC500156456. pdf. Accessed on March 5, 2014; 2013.
5. Canagliflozin (Invokana™) prescribing Information. NSW, Australia: Janssen-Cilag Pty Ltd. 2013.
6. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013;73:979-988.
7. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
8. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
9. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63:1879-1894.
10. GLUCOPHAGE™ prescribing information, Princeton NJ: Bristol-Myers Squibb; 2009.
11. Glucophage 500 mg and 850 mg film coated tablets. Summary of Product Characteristics (SPC). Merck Serono; 2010.
12. Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30:163-175.
13. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CAN-TATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941-950.
14. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-2592.
15. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232-1238.
16. Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267-1282.
17. Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467-477.
18. European Commission http://ec.europa.eu/health/documents/community-register/html/newproc. htm#h. Last accessed on April 15, 2014.
19. Devineni D, Curtin C, Ariyawansa J, Weiner S, Rusch S, Stielties H, Vaccaro N, Shalayda K, Murphy J, Di Prospero N, Wajs E. Bioequivalence of canagliflozin/metformin fixed-dose combination immediate release tablets compared with concomitant administration of single-components of canagliflozin and metformin in healthy fed participants. J Bioequiv Availab. Accepted for publication.
20. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 2008;25:1663-1676.
21. Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, Hanisch G, Lennernas H, Abrahamsson B. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res. 2005;22:2141-2151.
22. Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, Smith RL. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24:1118-1130.
23. Yasuji T, Kondo H, Sako K. The effect of food on the oral bioavailability of drugs: a review of current developments and pharmaceutical technologies for pharmacokinetic control. Ther Deliv. 2012;3:81-90.
24. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for Industry: Food-effect bioavailability and fed bioequivalence studies. 2002. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. Accessed on November 26, 2013.
25. EMEA Guideline on the Investigation of Bioequivalence. 2010 http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf. Accessed on March 10, 2014.
26. He YL, Flannery B, Campestrini J, Leon S, Zinny MA, Ligueros-Saylan M, Jarugula V. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin. 2008;24:1703-1709.
27. Karim A, Slater M, Bradford D, Schwartz L, Laurent A. Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. J Clin Pharmacol. 2007;47:48-55.
28. Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol. 2000;40:1494-1502.
29. Food and Drug Administration (FDA). Guidance for Industry, Bioanalytical Methods Validation. 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf. Accessed on 17 February, 2014.
30. Viswanathan C, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Workshop/conference report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007;9:E30-E42.
31. Devineni D, Manitpisitkul P, Murphy J, Stieltjes H, Ariyawansa J, Di Prospero NA, Rothenberg P, Ariyawansa J, Di Prospero NA, Rothenberg P. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clinical Pharmacology in Drug Development. 2014; n/a
32. Hong Y, Rohatagi S, Habtemariam B, Walker JR, Schwartz SL, Mager DE. Population exposureresponse modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008;48:696-707.
33. Sambol NC, Brookes LG, Chiang J, Goodman AM, Lin ET, Liu CY, Benet LZ. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol. 1996;42:510-512.